Baiduri Bank Opens Representative Office In Singapore
Yang Amat Mulia Pengiran Muda Dr Abdul Fattaah, Chairman of Baiduri Bank (Middle); Baiduri Bank Chief Executive Officer Ti Eng Hui (3-R); Board Member of Baiduri Bank Dato Paduka Timothy Ong Teck Mong (3-L); members of Baiduri Bank's management committee and Baiduri Bank's Chief Representative Officer Young Yi (2-L) at the launch of Baiduri Bank's Representative Office in Singapore
Since its establishment in 1994, Baiduri Bank has undergone a remarkable transformation—evolving from a home-grown bank into a leading financial institution that has played a pivotal role in Brunei's economic development. Its evolution over the past three decades has been marked by rapid growth, innovation, and expanded capabilities in retail, corporate, and institutional banking.
Today, Baiduri Bank is internationally recognised for its financial strength and innovation, reflected by its A-/A-2 stable rating from S&P Global Ratings. It has also been honoured with multiple international awards including 'Bank of the Year 2024" by The Banker, 'Best Bank in Brunei' by Euromoney and Global Finance, and 'Best Banking Group in Brunei 2024" by World Finance. These accolades reinforce the Bank's credibility and its strategic readiness to expand its regional footprint.
A strategic expansion into Singapore – Beyond Brunei
The launch of the Singapore Representative Office represents the next chapter in this trajectory. It is a strategic move to strengthen Baiduri Bank's regional presence, promote its corporate and institutional banking capabilities, and enhance engagement with counterparty banks and financial institutions.
Singapore, as one of the world's leading financial hubs, offers immense opportunities for the Bank to identify strategic partners and alliances. By acting as a bridge between Bruneian opportunities and Singapore's vibrant financial ecosystem, the office supports Brunei's economic diversification agenda while creating pathways for Singapore-based institutions and investors to access new markets and forge cross-border collaborations.
Leading the Representative Office
Leading the Baiduri Bank Representative Office is Mr Young Yi, Chief Representative Officer, a seasoned corporate banker with over 25 years of corporate banking experience across local and international banks, including Deutsche Bank, HSBC, Societe Generale, ANZ and Westpac. With a strong background in corporate banking, relationship management, Mr Young is a valuable addition to support Baiduri Bank's presence in Singapore.
Commenting on the launch, Mr Young stated: 'I am excited and privileged to be part of Baiduri Bank's journey in Singapore and I look forward to leveraging on my network, fostering strong meaningful collaborations to achieve win-win outcomes for Baiduri Bank and our partners. With our deep local knowledge of the Bruneian market, we offer ourselves as a trusted advisor to companies based in Singapore looking to invest in Brunei. The Representative Office will also serve as a referral conduit to our banking partners for Bruneian companies looking to expand into Singapore and the region'.
Strengthening regional economic collaboration
Brunei presents a compelling value proposition for businesses, offering a stable operating environment, strong governance, and attractive tax schemes. As a signatory to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), Brunei provides tariff-free access to one of the world's fastest-growing economic regions. With its well-educated workforce, absence of capital controls, and 1:1 currency interchangeability with the Singapore Dollar, Brunei is well-positioned as a gateway for regional business expansion.
In support of this goal, Baiduri Bank is working closely with the Brunei Economic Development Board (BEDB) to encourage greater investment engagement and regional business connectivity. The Bank's Singapore Representative Office will serve as a touchpoint to facilitate conversations with potential investors and explore new opportunities linked to Brunei. By aligning efforts with BEDB, Baiduri Bank hopes to contribute meaningfully to Brunei's broader economic diversification goals—while helping connect Bruneian businesses to regional markets and Singapore-based stakeholders to emerging opportunities in Brunei.
Launch and networking reception
The launch ceremony of Baiduri Bank's Singapore office at MBFC Tower 2 was a distinguished event, attended by esteemed guests, including Yang Amat Mulia Pengiran Muda Dr Abdul Fattaah, Chairman of Baiduri Bank, senior government officials, and prominent leaders from the banking sector of Brunei and Singapore.
Baiduri Bank's CEO, Ti Eng Hui, delivered an address outlining the Bank's vision for regional growth, followed by the unveiling of a meticulously crafted 3D replica of Baiduri Bank's headquarters presented alongside iconic landmarks of Brunei and Singapore – symbolising the strong economic ties between the two nations.
Following the official ceremony, Baiduri Bank hosted a networking cocktail reception at the Mandarin Oriental Singapore, attended by over 300 guests, including representatives and senior leaders from regional financial institutions and corporations.
Hashtag: #company #singaporeexpansion #bankingandfinance
https://www.baiduri.com.bn/
https://www.linkedin.com/company/baiduribankgroup/posts/?feedView=all
The issuer is solely responsible for the content of this announcement.
Baiduri Bank
Baiduri Bank Group is one of the largest providers of financial products and services in Brunei Darussalam. The Group comprises Baiduri Bank, Baiduri Finance and Baiduri Capital, providing banking services to institutions or corporations, retail banking, consumer financing, securities trading and wealth management.
Established in 1994, Baiduri Bank's shareholders include Baiduri Holdings and Darussalam Assets. With a combination of global outlook combined with extensive local knowledge and commitment to the Brunei market, the Bank has been acknowledged as the leading conventional bank in the country with a track record of financial innovations and pioneering activities.
In 2024, Baiduri Bank was awarded 'Bank of the Year 2024' by The Banker, 'Best Bank in Brunei 2023' by Euromoney, 'Best Bank in Brunei 2024' by Global Finance, 'Best Banking Group in Brunei 2024' by World Finance, 'Domestic Retail Bank of the Year, Brunei 2024' by the Asian Banking & Finance and 'Best Retail Bank in Brunei 2024' by the Asian Banker. The Bank was awarded the 2nd ASEAN Outstanding Social Welfare and Development Award (AOSWADA) in recognition of its CSR efforts in 2023.
Standard & Poor's maintained the Bank's credit rating to 'A-/A-2' with Stable Outlook in July 2024. https://www.baiduri.com.bn/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
MEXC Pushes into Southeast Asia With Deal Valuing Indonesian Exchange at $200 Million
Licensed crypto exchange Triv, based in Indonesia, has received a strategic equity investment from MEXC Ventures, the investment arm of global crypto platform MEXC. The deal values Triv at $200 million and reflects MEXC's growing focus on Southeast Asia, as Indonesia's crypto market enters a new phase of institutional participation and regulatory clarity. Leo Zhao, investment director at MEXC Ventures, told Decrypt the investment was 'structured as pure equity, not tokens or convertible instruments,' and is part of the group's broader expansion strategy in Southeast Asia. 'Triv's regulatory track record, user base, and infrastructure made it a high-conviction candidate,' he said, adding that the deal reflects MEXC's push to support 'local champions with strong compliance profiles' as institutional adoption grows across the region. MEXC Ventures declined to disclose the investment amount, citing a confidentiality agreement with Triv. The deal follows a major shift in Indonesia's crypto tax policy, which took effect as the month opened. Under a new finance ministry regulation, sellers of digital assets on domestic exchanges will now pay a 0.21% final income tax, at double the previous rate, while those using overseas platforms face a steeper 1% levy, per a Reuters report. Buyers, however, are no longer subject to value-added tax. Tokocrypto, a local exchange, said in the aforementioned report that the changes reflect Indonesia's shift in classifying crypto as a financial asset rather than a commodity, signaling a more formal regulatory phase for one of Southeast Asia's fastest-growing crypto markets. These measures are part of a broader transition in oversight from the commodities regulator BAPPEBTI to the Financial Services Authority (OJK), signaling a more institutional phase of market development. 'Natural fit' for expansion Zhao said the decision to back Triv stemmed from its 'proven market leadership' and alignment with local regulations, calling the Indonesian platform a 'natural fit for a long-term strategic partnership.' He noted that the timing reflects MEXC's wider ambitions to grow in high-potential, regulated markets across Southeast Asia. Founded in 2015, Triv is one of Indonesia's longest-running digital asset platforms. The exchange is fully licensed to offer spot trading, staking, and derivatives, and claims over 3 million registered users. It also operates a crypto media division, CryptoWave, and supports more than 1,000 digital assets including Bitcoin, Ethereum, meme coins, and synthetic U.S. stock products. Toncoin Jumps After '8-Figure' Investment by MEXC Ventures Triv said the deal would help expand products, boost liquidity, and strengthen infrastructure amid rising compliance demands. It will retain operational independence. MEXC Ventures signaled more regional investments may follow. The partnership would allow Triv to scale while maintaining its identity, Zhao said. 'For Triv's users, partnership with MEXC means enhanced services and reliability coupled with the core values and independence that have earned their trust over the last nine years,' he told Decrypt. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
US Futures point higher, BP and Palantir earnings beat: 3 Things
The three things you need to know before that opening bell rings are that after a tumultuous week on Wall Street - US futures are heading higher after Monday's stellar performance, BP (BP) vows to give more to investors and Palantir (PLTR) reported its first ever $1 billion quarterly revenue. Okay. The first thing you need to know before that opening bell rings is that after a tumultuous week on Wall Street, US Futures, well, they're heading higher. As you can see, it's green across the board. On Monday, stocks rebounded sharply after taking on Friday, in the aftermath, tanking on Friday in the aftermath of a number of market shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices and the firing of the Commissioner of the Bureau of Labor Statistics. That tariff threat hasn't gone away. Yesterday, President Trump threatened to hike tariffs on India. He's angry about the Southeast Asian countries purchases of Russian oil. Last month, Washington announced that India would be hit with a 25% levy on its exports to the US. For its part, New Delhi has hit back at the President's threat. It said it would take all necessary steps to protect its economic interests. The next thing to know about before that opening bell rings is that oil major BP has reported better than expected second quarter results. BP reported adjusted profits of $2.4 billion for the period, a third higher than analysts expected. And it's raised its quarterly dividend by 4%. The company maintained a $750 million quarterly share buyback too. However, BP said that it will review its portfolio of assets and consider more cost cuts as part of a drive to do better for shareholders under pressure to improve profitability. Not least from activist investor, US hedge fund Elliott Management. CEO, Murray Auchinloss, earlier this year announced plans to sell $20 billion of assets through to 2027, as well as to cut spending, debt and costs. Today, he signalled further action, but without giving details. The quarterly performance benefited from a 33% increase in profits at BP's customers and products business, driven by strong oil trading results, higher volumes, and a 20% rise in earnings at its Castrol lubricants unit, which the company plans to sell. BP shares listed in London rose in response. Its shares listed in New York are also set to rise when the opening bell rings too. Now remember that BP shares have underperformed its rivals since its 2020 shift towards renewables under former CEO, Bernard Looney. That's a policy that's firmly in reverse. And the final thing to know about before the opening bell rings is again focused on earnings. Palantir reported a 48% increase in revenue for the second quarter to more than $1 billion, citing the astonishing impact of artificial intelligence technology on its business. And as you can see, that's having quite the impact on its share price in the premarket. It's up over 5%, as you can see there. It's on track to hit an all time high when the New York markets open.
Yahoo
4 hours ago
- Yahoo
US-China tensions offer new opportunity for APAC biotechs, report suggests
Investors are increasingly focused on biotech companies outside of China operating in the Asia-Pacific (APAC) market, according to a report by management consulting firm Bain & Company. Homing in on Singapore specifically, the report states that rising players within the APAC region are drawing in investors through their political neutrality, protection of intellectual property (IP) and strong healthcare infrastructure. This trend is further driven by continued investment by the Singaporean Government, which has handed out $25bn in early-stage funding between 2021 and 2025 through its Research Innovation and Enterprise 2025 (RIE2025) scheme. Singapore is also aiming to bridge the gap between academia and industry through its A*STAR scheme, which is designed to encourage the translation of research into commercially viable drugs. These initiatives are designed to de-risk the early-stage development process, laying the foundations for future venture capital investment. Changing tides in the biotech sector The 2020s have been a tough period for the biotech industry, with many companies failing to obtain funding amid growing geopolitical instability and a sharpened investor focus on late-stage therapies. However, things may be looking up for the sector, with a GlobalData report finding that biotech companies obtained $8.52bn in 2024 through initial public offerings (IPOs) — a marked increase from the $5.06bn raised in 2023. Though the US and China continue to dominate the market, rising tensions between the nations could shift the balance towards politically neutral and stable nations, stated Alison Labya, senior pharma business fundamentals analyst at GlobalData. Labya said: 'Singapore's alignment with international pharmaceutical standards reduces legal and regulatory risk, increasing investor confidence in the commercial potential of innovative drugs." As the US continues to face geopolitical uncertainty, NIH funding cuts and mass regulatory layoffs, Labya noted that APAC players — particularly Singapore — are emerging as attractive alternatives for biotech investors, offering a more stable environment conducive to bringing drugs to market. Biotech's future moving forward Even amidst the growing geopolitical tensions between the US and China, Labya stated that China will likely remain the dominant force in Asian biotech. 'China remains resilient in the face of Trump's trade war, notably retaliating with 125% tariffs on US goods in April 2025,' Labya commented. Through this response, both countries reduced their import tariff rates, highlighting China's capacity to influence trade and policy outcomes. Large pharma has also continued to engage with the Chinese biotech market, with 28% of innovator drugs now being picked up from the nation, according to a report from GlobalData. For APAC countries such as Singapore to compete with China, Labya noted that biotechs in the region must penetrate the US and EU, requiring expertise into the FDA and EMA's regulatory frameworks, as well as the development of international partnerships. "US-China tensions offer new opportunity for APAC biotechs, report suggests" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
